

Bakteriophagen – Therapie und CRISPR/Cas

d'Hérelle F (1917) Sur un microbe invisible antagoniste des bacilles dysentérique. Acad Sci Paris. 165, 373–5.

d'Hérelle F (1921) Le bacteriophage. La Nature (Paris) 49, 219–22

d'Hérelle F (1926) Le Bactériophage et Son Comportement. Paris et Cie

Rice TB (1930) Use of bacteriophage filtrates in treatment of conditions: Report of 300 cases. Am J Med Sci. 179, 345–60

Eaton MD, Bayne-Jones S (1934) Bacteriophage therapy. [JAMA](#), 103, 1769-76, 1847-53, 1934-39.

D'Hérelle F. (1936) Traitement et prophylaxie par le bactériophage des maladies épidémiques de nature bactérienne. Le bactériophage. Applications thérapeutiques. La Médecine. 17(Suppl 2), 23–32.

d'Herelle F (1948/1949) Le bactériophage. Atomes, 3, 399-403. (Translated in Sci News, 14, 44-59, 1949.)

Hershey AD, Chase M (1952) Independent Functions of Viral Protein and Nucleic Acid in Growth of Bacteriophage. [J Gen Physiol](#), 36, 39-56

Duckworth DH (1976) Who discovered bacteriophage? [Bacteriol Rev](#), 40, 793–802

Botstein D (1980) A theory of modular evolution for bacteriophages. Ann N Y Acad Sci 354, 484-490.

Ioseliani GD, Meladze GD, Chkhetiia NS et al. (1980) **Use of bacteriophage and antibiotics for prevention of acute postoperative empyema in chronic suppurative lung diseases.** Grudn. Khir. (Rus)

Ackermann H-W, DuBow M. (1987) Practical Applications of Bacteriophages. Florida: CRC Press; Viruses of Prokaryotes I: General Properties of Bacteriophages.

Cisło M, Dabrowski M, Weber-Dabrowska B et al. (1987) **Bacteriophage treatment of suppurative skin infections.** Arch Immunol Ther Exp (Warsz) 35(2), 175-83
<http://www.ncbi.nlm.nih.gov/pubmed/3447533>

Bull JJ, Levin BR. (1996) Phage therapy revisited: The population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. Am Nat. 147, 881–98

Merill CR et al. (1996) Long circulating bacteriophages as antibacterial agents. PNAS 93, 3188-3192

(1997) Phage - The Virus that Cures [Video, 49 min.](#) <http://topdocumentaryfilms.com/phages-the-virus-that-cures/>

[Richardson JF](#), [Rosdahl VT](#), [van Leeuwen WJ](#) et al. (1999) **Phages for methicillin-resistant Staphylococcus aureus: an international trial.** Epidemiol Infect. 122(2), 227–233.
PMCID: PMC2809610 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809610/>

[Mathur MD](#), [Mehndiratta PL](#) (2000) **Characterization of methicillin resistant Staphylococcus aureus strains by a set of MRSA phages.** [Indian J Med Res.](#) 111, 77-80.
<http://www.ncbi.nlm.nih.gov/pubmed/10937382>

Carlton RM (1999) **Phage therapy: past history and future prospects.** Arch. Immunol. Ther. Exp. 47(5), 267-74 <http://www.ncbi.nlm.nih.gov/pubmed/10604231>

Weber-Dabrowska B, Mulczyk M, Gorski A. (2000) Bacteriophage therapy of bacterial infections: An update of our institute's experience. Arch Immunol Ther Exp. 48, 547–51.

- Summers WC (2001) **Bacteriophage therapy**. *Ann Rev Microbiol.* 55, 437–51. [PubMed](#)
- Sulakvelidze A, Alavidze Z, Morris JG (2001) **Bacteriophage therapy**. *Antimicrob Agents Chemother.* 45, 649–59. [PMC free article PubMed](#)
- Kono M, Hoshina S, Machida K (2004) **Phage set for methicillinresistant Staphylococcus aureus (MRSA) strains combined with the international phage typing set and the phages from coagulase-negative staphylococci**. <http://www.jscm.org/journal/full/01402/014020092.pdf>
- Schoolnik GK, Summers WC, Watson JD (2004) Phage offer a real alternative. *Nat Biotechnol.* 22, 505–6. [PubMed](#)
- Hänggi BJ (2004) Die Phagentherapie und das Problem der Verwirklichung. Inauguraldissertation, Universität Bern. http://www.stub.unibe.ch/download/eldiss/04haenggi_b.pdf
- Thiel K (2004) **Old dogma, new tricks—21st Century phage therapy**. In: Nature Publishing Group (Hrsg.): *Nature Biotechnology.* 22(1), 31–36. [PMID 14704699](#).
- Nancy A. et al. (2005) The players in a mutualistic symbiosis: Insects, bacteria, viruses, and virulence genes. [PNAS](#), 102, 6919-26
- André M. et al. (2005) War is peace—dispatches from the bacterial and phage killing fields. [Curr Opin Microbiol](#), 8, 488-94
- Jones JB et al. (2007) Bacteriophages for plant disease control. [Annu Rev Phytopathol](#), 45, 245-62
- Fruciano E. (2007) Phage as an antimicrobial agent: d’Herelle’s heretical theories and their role in the decline of phage prophylaxis in the West *Can J Infect Dis Med Microbiol.* 18(1), 19–26.
- [Miedzybrodzki R¹](#), [Fortuna W](#), [Weber-Dabrowska B](#), [Górski A](#). (2009) A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses, [Clin Exp Med](#), 9, 303-12. <http://www.ncbi.nlm.nih.gov/pubmed/19350363>
- [Rhoads DD](#), [Wolcott RD](#), [Kuskowski MA](#) et al. (2009) Bacteriophage therapy of venous leg ulcers in humans: Results of a Phase I safety trial. [J Wound Care](#), 18, 237-38, 240-43. <http://www.ncbi.nlm.nih.gov/pubmed/19661847>
- Willner D et al. (2010) Colloquium paper: Metagenomic detection of phage-encoded platelet-binding factors in the human oral cavity. [PNAS](#), 108, 4547-53
- Debarbieux L et al. (2010) Bacteriophages can treat and prevent *Pseudomonas aeruginosa* lung infections. [J Infect Dis](#), 201, 1096-104
- Colomer-Lluch M, Imamovic L, Jofre J, Muniesa M (2011) Bacteriophages Carrying Antibiotic Resistance Genes in Fecal Waste from Cattle, Pigs, and Poultry. *Antimicrobial Agents and Chemotherapy*, 55 (10), 4908 DOI: [10.1128/AAC.00535-11](https://doi.org/10.1128/AAC.00535-11)
- Colomer-Lluch M, Muniesa JJM. (2011) Antibiotic Resistance Genes in the Bacteriophage DNA Fraction of Environmental Samples. *PLoS ONE*, 6 (3), e17549 DOI: [10.1371/journal.pone.0017549](https://doi.org/10.1371/journal.pone.0017549)
- Fancello L, Desnues C, Raoult D (2011) Bacteriophages and diffusion of genes encoding antimicrobial resistance in cystic fibrosis sputum microbiota. *Antimicrob Chemother.* 66(11), 2448-54.
- Rolain JM, Fancello L, Desnues C, Raoult D (2011) Bacteriophages as vehicles of the resistome in cystic fibrosis. [J Antimicrob Chemother.](#) 66(11), 2444-7.
- Ackermann HW (2011) The first phage electron micrographs. [Bacteriophage](#), 1, 225-27
- Abedon ST et al, (2011) Phage treatment of human infections. [Bacteriophage](#), 1, 66-85.
- Raack R. (2012) Phagentherapie. <http://www.raack.de/phage/index.html>

Youle M. et al. (2012) Scratching the surface of biology's dark matter. [Viruses: Essential Agents of Life](#), ed. Günther Witzany (Springer Netherlands), 61-81

Swanson MM. et al. (2012) Novel bacteriophages containing a genome of another bacteriophage within their genomes. [PLOS ONE](#), 7, e40683

Metcalf JA, Bordenstein SR (2012) **The complexity of virus systems: the case of endosymbionts**, *Curr Opin Microbiol* <http://dx.doi.org/10.1016/j.mib.2012.04.010> <http://www.ncbi.nlm.nih.gov/pubmed/22609369>

Snitkin ES et al. (2012) Tracking a hospital outbreak of carbapenem-resistant *Klebsiella pneumoniae* with whole-genome sequencing, [Sci Transl Med](#), 4, 148ra116

[Międzybrodzki R](#), [Borysowski J](#), [Weber-Dąbrowska B](#) et al. (2012) Clinical aspects of phage therapy. [Adv Virus Res](#), 83, 73-121 <http://www.ncbi.nlm.nih.gov/pubmed/22748809>

Brüssow H (2013) Bacteriophage–host interaction: From splendid isolation into a messy reality. [Curr Opin Microbiol](#), doi:10.1016/j.mib.2013.04.007

Sheetal R et al. (2013) Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome. [Nature](#), doi:10.1038/nature12212

McCallin S. et al. (2013) Safety analysis of a Russian phage cocktail: From MetaGenomic analysis to oral application in healthy human subjects. [Virology](#), 443, 187-96

Seed KD. et al. (2013) A bacteriophage encodes its own CRISPR/C as adaptive response to evade host innate immunity. [Nature](#), 494, 489-91

[Barr JJ](#), [Auro R](#), [Furlan M](#) (2013) Bacteriophage adhering to mucus provide a non–host-derived immunity. *PNAS*. doi:10.1073/pnas.1305923110. <http://www.pnas.org/content/early/2013/05/16/1305923110>

[Łusiak-Szelachowska M](#), [Zaczek M](#), [Weber-Dąbrowska B](#) et al., (2014) Phage neutralization by sera of patients receiving phage therapy," [Viral Immunol](#), 27, 295-304. <http://www.ncbi.nlm.nih.gov/pubmed/24893003>

Brown-Jaque M, Calero-Cáceres, Muniesa M (2015) Transfer of antibiotic-resistance genes via phage-related mobile elements. *Plasmid*. <http://www.sciencedirect.com/science/article/pii/S0147619X15000116>

Yosef I et al. (2015) Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. *PNAS*, doi:10.1073/pnas.1500107112. <http://www.pnas.org/content/early/2015/05/14/1500107112>

Barr JJ et al. (2015) Subdiffusive motion of bacteriophage in mucosal surfaces increases the frequency of bacterial encounters, [PNAS](#), 112, 13675-80.

Hardes K, Köhler SM, Beyer, W et al. (2015) **Novel furin inhibitors with potent anti-infectious activity**. *ChemMedChem*. - Weinheim [u.a.] : Wiley-VCH, ISSN 1860-7187. 10(7), 1218-1231 <http://www.ncbi.nlm.nih.gov/pubmed/25974265>

Lekunberri I et al. (2016) **Exploring the contribution of bacteriophages to antibiotic resistance**, *Environmental Pollution*, doi:10.1016/j.envpol.2016.11.059.

- ➔ **Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (2016) Bakteriophagen und Phagentherapie.** <https://www.dsmz.de/de/start/aktuelles/phagen-infoseite.html>
- ➔ **Antibiotikaresistente Bakterien, antibiotic resistant bacteria** <http://www.erlebnishaft.de/staphylococcus aureus.pdf>
- ➔ **Horizontaler Gentransfer** <http://www.erlebnishaft.de/gentransfer.pdf>

Bakteriophagen gewerblich Bacteriophages commercial

COMPANY	LOCATION	PRODUCTS	APPLICATIONS	IN TRIALS?
AmpliPhi	Richmond, Virginia	Natural phage cocktails	P. aeruginosa lung infections in cystic fibrosis; S. aureus wound and skin infections; C. difficile gastrointestinal infect	Phase 1 approved November 2015
ContraFect Corporation	Yonkers, New York	Bacteriophage lysins	S. aureus bacteremia	Phase 1 launched April 2015
Pherecydes	Romainville, France	Natural phage cocktails	E. coli and P. aeruginosa burn and skin infections; P. aeruginosa respiratory infections; S. aureus bone/joint/prosthetic infect	Phase 1 launched September 2015
JSC Biopharm	Georgien	Natural phage cocktails	See appropriate section	See appropriate section

➔ **A sampling of firms that are conducting research on viral treatments for bacterial infections.** Selection above according to <http://www.the-scientist.com/?articles.view/articleNo/44785/title/Viral-Soldiers/>

Immunisierung von Bakterien gegen Phagen, Immunizing bacteria against phages. CRISPR/Cas, the Immune System of Bacteria and Archaea

„Die CRISPR/Cas-Methode (Clustered Regularly Interspaced Short Palindromic Repeats) ist eine biochemische Methode, um DNA gezielt zu schneiden und zu verändern (**Genome Editing**). Gene können mit dem CRISPR/Cas-System eingefügt, entfernt oder ausgeschaltet werden, Nukleotide in einem Gen können geändert werden“.
Quelle: <https://de.wikipedia.org/wiki/CRISPR/Cas-Methode>

Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A (1987) **Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product.** J Bacteriol 169, 5429–5433

Mójica FJ et al. (2005) Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. [J Mol Evol](#), 60, 174-82.

Bolotin A et al. (2005) Clustered regularly interspaced short palindrome repeats (**CRISPRs**) have spacers of extrachromosomal origin. [Microbiology](#), 151, 2551-61.

Barrangou R et al. (2007) **CRISPR** provides acquired resistance against viruses in prokaryotes. 315, 1709-12

Doudna J (2009) **Genome Engineering with CRISPR-Cas9**
<https://www.youtube.com/watch?v=SuAxDVbt7kQ#t=64.724852>

Horvath A, Barrangou R (2010) **CRISPR/Cas, the Immune System of Bacteria and Archaea.**
[Science](#) 327, 167

Makarova KS et al. (2011) Evolution and classification of the **CRISPR-Cas systems.** [Nat Rev Microbiol](#), 9:467-77.

Mina Rho, Yu-Wei Wu, Haixu Tang et al. (2012) **Diverse CRISPRs Evolving in Human Microbiomes.** PLOS Genetics 8(6), e1002441

Mali P, Yang L, Esvelt KM et al. (2013) **RNA-guided human genome engineering via Cas9.** Science (New York, N.Y.). 339(6121), 823–826, [ISSN 1095-9203](#). [doi:10.1126/science.1232033](#). [PMID 23287722](#). [PMC 3712628](#) (freier Volltext).

Seed et al. KD (2013) A bacteriophage encodes its own **CRISPR/Cas** adaptive response to evade host innate immunity," [Nature](#), 494, 489-91.

Krupovic M et al. (2014) Casposons: a new superfamily of self-synthesizing DNA transposons at the origin of prokaryotic **CRISPR-Cas** immunity," [BMC Biology](#), 12, 36.

Doudna J, Charpentier, E (2014) **The new frontier of genome engineering with CRISPR-Cas9.** Science 346(6213), 1077 [doi:10.1126/science.1258096](#)

Barrangou R, Marraffini LA (2014) **CRISPR-Cas** systems: Prokaryotes upgrade to adaptive immunity. [Mol Cell](#), 54, 234-44.

Grens K (2015) **Dairy Engineering** How DuPont uses **CRISPR** to keep yogurt and cheeses safe from bacteriophage attack.
<http://www.the-scientist.com//?articles.view/articleNo/41829/title/Dairy-Engineering/>

Puping Liang P, Yanwen Xu Y, Xiya Zhang X et al. (2015) **CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes.** Protein & Cell. 6, 363, [doi:10.1007/s13238-015-0153-5](#).

Fulco CP et al. (2016) **Systematic mapping of functional enhancer-promoter connections with CRISPR interference.** Science, doi:10.1126/science.aag2445.

Sanjana NE et al. (2016) **High-resolution interrogation of functional elements in the noncoding genome.** Science, doi:10.1126/science.aaf8325.

[Bernt-Dieter Huismans](#), Last revision december 2016 www.Huismans.click

Back to top: <http://www.kabilahsystems.de/bakteriophagen.pdf>

